Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -16.65
- Piotroski Score 1.00
- Grade Underweight
- Symbol (TCDA)
- Company Tricida, Inc.
- Price $0.11
- Changes Percentage (0%)
- Change -$0
- Day Low $0.09
- Day High $0.12
- Year High $13.85
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/27/2023
- Fiscal Year End N/A
- Average Stock Price Target $16.00
- High Stock Price Target $16.00
- Low Stock Price Target $16.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.29
- Trailing P/E Ratio -0.020404307576044
- Forward P/E Ratio -0.020404307576044
- P/E Growth -0.020404307576044
- Net Income $-194,168,000